Broker Forsyth Barr has released the first comprehensive report into Dunedin-based biotech company Pacific Edge [NZX: PEB], and its outlook is positive, pleasing one investor Aaron Bhatnagar.
The New Zealand maker of non-invasive bladder cancer test kits Cxbladder has just launched a local
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Calida Smylie
Thu, 31 Jul 2014
Thu, 31 Jul 2014
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Analyst optimistic about NZX-listed cancer-test maker
40054